{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-180814","form_type":"8-K","ticker":"PSTV","cik":"0001095981","company_name":"PLUS THERAPEUTICS, INC.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.327867+00:00","generated_at":"2026-05-17T12:47:15.261042+00:00","sec_items":["8.01","9.01"],"event_type":"other","sentiment":"positive","materiality_score":0.7,"confidence":"high","headline":"Plus Therapeutics Regains Nasdaq Compliance; Reports $3M Stockholders' Equity and $35M+ MVLS","bullets":["Reported stockholders' equity of $3M as of June 30, 2025, satisfying Nasdaq's minimum $2.5M Equity Rule.","Sold over $2M in common stock via a $50M equity line of credit with Lincoln Park Capital Fund since June 30.","As of August 13, 2025, market value of listed securities exceeded $35M for 20 consecutive business days, meeting the alternative MVLS requirement.","Company awaits formal Nasdaq confirmation that it has evidenced compliance with either or both listing standards."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-180814","json":"https://secwatch.observer/filing/0001193125-25-180814.json","markdown":"https://secwatch.observer/filing/0001193125-25-180814.md","text":"https://secwatch.observer/filing/0001193125-25-180814.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1095981/000119312525180814/0001193125-25-180814-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1095981/000119312525180814/d824499d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T12:47:15.261042+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}